MarketPulse

radioligand therapy

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Expands Radioligand Therapy Network with Texas Facility Groundbreaking

Novartis broke ground on a $46K sq. ft. radioligand therapy facility in Texas, the fifth RLT site supporting its $23B US manufacturing investment ending in 2028.
NVSsupply chainpersonalized medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Expands RLT Empire: Texas Facility Part of $23B US Manufacturing Push

Novartis broke ground on a Texas radioligand therapy facility, the fifth in its US network, part of a $23 billion manufacturing investment expected operational by 2028.
NVSsupply chainpersonalized medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Telix Pharmaceuticals Limited

Telix's Next-Gen Prostate Cancer Drug Shows Promise With Lower Toxicity Profile

Telix's next-gen prostate cancer therapy shows reduced organ toxicity in Phase 2 trial, expanding into earlier-stage disease applications with expanded clinical potential.
TLXclinical trialprostate cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Rare Cancer Drug Market Surges 7.3% Annually as Novel Therapies Transform PCPG Treatment

PCPG cancer market projects 7.3% annual growth through 2036, valued at USD 300M in 2025, driven by novel drug classes and Novartis WELIREG leadership.
MRKNVSBHCCATXJAZZmarket growthradioligand therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

PYLARIFY Makes History as First Blockbuster Radiodiagnostic Amid PSMA Market Expansion

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.
NVSLNTHPET imagingPYLARIFY